Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
Company Overview
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders.
| Name: | Alexion Pharmaceuticals Inc. |
|---|---|
| Address: | 352 Knotter Drive Cheshire, Connecticut 06410-1138 |
| Phone: | (203) 272-2596 |
| Email: | AdlerI@alxn.com |
| Web site: | www.alxn.com |
| CEO: | NA |
| % Owned By | Shares Bought In Last 90 Days | Shares Sold In Last 90 Days | |
| Insiders | NA | 60,784 | 155,367 |
| Institutional | 99.98% | NA | NA |
| Change in Short Interest as of 3/15/2013 | -8.57% | ||
| Short Interest as % of Float as of 3/15/2013 | 2.11% | ||
| Number of Employees | 1,373 |
|---|---|
| Revenue per Employee | $816,639 |
| Income per Employee | $185,595 |
| Market Capitalization (thousands) | $19,364,700 |
| Enterprise Value (thousands) | $17,146,078 |
| Auditors Opinion | Unqualified |
Officers and Directors
Max E Link, Leonard Bell, Vikas Sinha, Camille L Bedrosian, Stephen P Squinto, Thomas Bock, M Stacy Hooks, James P Bilotta, Henric Bjarke, Frank J Wright, Margaret M Olinger, Sven Ante Lundberg, Daniel N Caron, Jeremy P Springhorn, David L Hallal, Jeroen van Beek, R Douglas Norby, William Robert Keller, Larry L Mathis, Ann Margaret Veneman, Alvin S Parven, Joseph A Madri, Andreas Rummelt, Irving Adler, Kim Diamond
